search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Company insight Microbiology’s


merits when assessing antimicrobial resistance


Antimicrobial resistance is a growing problem partially due to the high levels of antibiotics that are administered in healthcare departments across the world – but how can microbiologists help? Beckman Coulter, manufacturer of the MicroScan range of microbiology testing instruments, asks one of its customers, Dr Giancarlo Basaglia, head of the department of microbiology and virology at the Western Friuli Health Authority (AS FO).


Why should antimicrobial resistance be a priority for the healthcare sector? Dr Giancarlo Basaglia: Antimicrobial resistance is a significant clinical and public health issue, and a large part of the problem is resistance to antibiotics. People have been aware of this situation for a long time, and despite numerous useful initiatives, unless more effective action is carried out, the situation will deteriorate within the next few years.


How does that initial diagnosis allow microbiology professionals to perform the subsequent stages? Diagnosis is the daily work of microbiology professionals and it is also propaedeutic to the stages that follow. Diagnosis must be appropriate, within a time frame that meets clinical requirements and in line with the indications outlined in literature by various scientific associations and healthcare organisations.


“Among the many important areas involved, microbiology plays several specific roles.”


How does microbiology play a role in understanding and tackling antimicrobial resistance? Among the many important areas involved, microbiology plays several specific roles. It is vital in the diagnosis of microorganisms causing infection and the subsequent testing of their sensitivity to numerous antimicrobials. It enables us to then collect data on these microorganisms from an epidemiological standpoint. Microbiology also allows for the monitoring and prompt reporting of the most critical microorganisms in terms of aggressiveness and resistance to antimicrobials. This process and the data it produces helps significantly in consultation at all levels of healthcare, as well as the training of professionals and further research and study in the sector.


Practical Patient Care / www.practical-patient-care.com


Microbiological diagnosis is very important due to its clinical significance, but also because it is the basis for the majority of surveillance and epidemiology. The latter is important because it raises awareness about the situation and spread of microorganisms caused by infections and their resistance to antimicrobials on a local, national and international level.


How does collaboration play a part in tackling antimicrobial resistance?


Collaboration and surveillance networks are important when dealing with microorganisms and assessing their levels of resistance. Working together and benefiting from multiple forms of surveillance means we can analyse specific resistances to antibiotics and compare the results on a range of


different levels. When it is possible to see the results of a particular antibiotic resistance from a number of regions, crucial steps can be taken in an effort to analyse potential causes and put forward improvement measures. This collaboration between regions and organisations is vital.


How has the Covid-19 pandemic affected the increase in antibiotic resistance microbes?


The Covid-19 pandemic is an example of how epidemiology can be used to assess new and urgent situations effectively. Studies have shown that those who suffer with Covid-19 also exhibit a considerable increase in resistance towards antibiotic treatment for infections such as methicillin- resistant Staphylococcus aureus (MRSA) and bacteria that produce extended spectrum beta-lactamases (ESBL) resistance to carbapenems (KPC) and quinolones. This represents a serious problem for these patients both when suffering from Covid-19 and in the post- Covid-19 phase, and also due to the potential spread of more aggressive microorganisms from these patients to others. While the emphasis is still very much on the Covid-19 pandemic, the pandemic of antimicrobial resistance demands that surveillance remains high and that more effective initiatives be established to support the continuing fight against it. ●


Research in collaboration with M Busetti, A Sartor, R De Rosa, M Gobbato, E Clagnan and L Arnoldo.


www.beckmancoulter.com 17


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63